Session :
Dual antiplatelet treatment duration in Acute Coronary Syndrome (ACS) - Percutaneous Coronary Intervention (PCI): one for all or all for one?
Session :
Dual antiplatelet treatment duration in Acute Coronary Syndrome (ACS) - Percutaneous Coronary Intervention (PCI): one for all or all for one?
Session :
Overcoming the dilemma of stroke versus bleeding in non-valvular atrial fibrillation: can we optimise patient care with oral factor Xa inhibition
Speaker : H
Bueno
(Madrid,ES), G
Montalescot
(Paris,FR)
Sponsored by Bristol-Myers Squibb and Pfizer Alliance
Session :
Overcoming the dilemma of stroke versus bleeding in non-valvular atrial fibrillation: can we optimise patient care with oral factor Xa inhibition
Speaker : G
Montalescot
(Paris,FR), A
Goette
(Paderborn,DE), J
Alexander
(Durham,US), P
Kirchhof
(Edgbaston,GB), S
Connolly
(Hamilton,CA)
Sponsored by Bristol-Myers Squibb and Pfizer Alliance
Session :
New frontiers, novel mechanisms, and evolving paradigms for optimizing cardiovascular risk reduction in patients with type 2 diabetes and acute coronary syndrome
Session :
Early initiation of antiplatelet therapy: pre-treatment in ACS, facts and fictions
Speaker : G
Montalescot
(Paris,FR)
Organised by Leiden University Medical Centre / Course Director: Prof. Wouter Jukema / Programme supported by an unrestricted educational grant from Daiichi Sankyo and Eli Lilly and Company
ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.
Our mission: To reduce the burden of cardiovascular disease